Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study
Advances in Therapy · 2024
DOI: 10.1007/s12325-024-02827-8 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Advances in Therapy, 2024. Verfasst von Christopher J Patriquin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hematology & Apheresis Medicine, University Health Network, Toronto General Hospital, Toronto, ON, Canada. Christopher.Patriquin@uhn.ca. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Apellis Pharmaceuticals, Swedish Orphan Biovitrum.
Abstract (Originalsprache)
INTRODUCTION: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening disease characterized by complement-mediated hemolysis and thrombosis. Pegcetacoplan, the first targeted complement component 3 (C3) PNH therapy, was safe and efficacious in treatment-naive and pre-treated patients with PNH in five clinical trials. METHODS: The 307 open-label extension (OLE) study (NCT03531255) is a non-randomized, multicenter extension study of long-term safety and efficacy of pegcetacoplan in adult patients with PNH who completed a pegcetacoplan parent study. All patients received pegcetacoplan. Outcomes at the 48-week data cutoff (week 48 of 307-OLE or August 27, 2021, whichever was earlier) are reported. Hemoglobin concentrations, Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scores, and transfusion avoidance were measured. Hemoglobin > 12 g/dL and sex-specific hemoglobin normalization (i.e., male, ≥ 13.6 g/dL; female, ≥ 12 g/dL) were assessed as percentage of patients with data available and no transfusions 60 days before data cutoff. Treatment-emergent adverse events, including hemolysis, were reported. RESULTS: Data from 137 patients with at least one pegcetacoplan dose at data cutoff were analyzed. Mean (standard deviation [SD]) hemoglobin increased from 8.9 (1.22) g/dL at parent study baseline to 11.6 (2.17) g/dL at 307-OLE entry and 11.6 (1.94) g/dL at data cutoff. At parent study baseline, mean (SD) FACIT-Fatigue score of 34.1 (11.08) was below the general population norm of 43.6; scores improved to 42.8 (8.79) at 307-OLE entry and 42.4 (9.84) at data cutoff. In evaluable patients, hemoglobin > 12 g/dL occurred in 40.2% (43 of 107) and sex-specific hemoglobin normalization occurred in 31.8% (34 of 107) at data cutoff. Transfusion was not required for 114 of 137 patients (83.2%). Hemolysis was reported in 23 patients (16.8%). No thrombotic events or meningococcal infections occurred. CONCLUSION: Pegcetacoplan sustained long-term improvements in hemoglobin concentrations, fatigue reduction, and transfusion burden. Long-term safety findings corroborate the favorable profile established for pegcetacoplan. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT03531255.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology & Apheresis Medicine, University Health Network, Toronto General Hospital, Toronto, ON, Canada. Christopher.Patriquin@uhn.ca.
- Clinic of Hematology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
- Department of Haematology, St. James's University Hospital, Leeds, UK.
- Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
- Hematology Oncology of Indiana, Indianapolis, IN, USA.
- Ascension St. Vincent Carmel, Carmel, IN, USA.
Förderung
- Apellis Pharmaceuticals
- Swedish Orphan Biovitrum
Zitieren
APA
Patriquin, C. J., Bogdanovic, A., Griffin, M., Kelly, R. J., Maciejewski, J. P., Mulherin, B., Peffault de Latour, R., Röth, A., Selvaratnam, V., Szer, J., Al-Adhami, M., Horneff, R., Tan, L., Yeh, M., & Panse, J. (2024). Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study. Advances in Therapy. https://doi.org/10.1007/s12325-024-02827-8
Vancouver
Patriquin CJ, Bogdanovic A, Griffin M, Kelly RJ, Maciejewski JP, Mulherin B, et al. Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study. Advances in Therapy. 2024. doi:10.1007/s12325-024-02827-8
BibTeX
@article{Patriquin2024,
author = {Patriquin, Christopher J and Bogdanovic, Andrija and Griffin, Morag and Kelly, Richard J and Maciejewski, Jaroslaw P and Mulherin, Brian and Peffault de Latour, Régis and Röth, Alexander and Selvaratnam, Veena and Szer, Jeffrey and Al-Adhami, Mohammed and Horneff, Regina and Tan, Lisa and Yeh, Michael and Panse, Jens},
title = {Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study},
journal = {Advances in Therapy},
year = {2024},
doi = {10.1007/s12325-024-02827-8}
}
EUVIMED